PDF(Pubmed)
Abstract：
UNASSIGNED: Additive human menopausal gonadotropin (HMG)/recombinant luteinizing hormone (r-LH) to follicle-stimulating hormone (FSH) can improve pregnancy outcomes in patients with poor ovarian response during assisted reproductive procedures. However, their effects on patients with normal ovarian response during such procedures are unclear, which formed the aim of this study.
UNASSIGNED: This retrospective study enrolled 456 infertile women who underwent in vitro fertilization or intracytoplasmic sperm injection treatment. Group 1 received FSH; Group 2 received FSH+HMG/r-LH; Group 3 received FSH+HMG+r-LH.
UNASSIGNED: The age and Body Mass Index were significantly greater in Group III. The endometrial thickness was greater in Groups II and III, suggesting better endometrial receptivity. Better pregnancy and birth outcomes were seen in Group 3. In sub-cohorts of women older than 32 years old or with overweight/obesity, pregnancy and birth outcomes were also much better in Group 3, albeit without statistical significance.
UNASSIGNED: The addition of both HMG and r-LH to FSH may improve the chance of infertile women with normal ovarian responses to have more success in having live birth babies, specifically in those over 32 years of age or with overweight/obese patients who typically face challenges in conceiving and sustaining a pregnancy.
UNASSIGNED: This retrospective study enrolled 456 infertile women who underwent in vitro fertilization or intracytoplasmic sperm injection treatment. Group 1 received FSH; Group 2 received FSH+HMG/r-LH; Group 3 received FSH+HMG+r-LH.
UNASSIGNED: The age and Body Mass Index were significantly greater in Group III. The endometrial thickness was greater in Groups II and III, suggesting better endometrial receptivity. Better pregnancy and birth outcomes were seen in Group 3. In sub-cohorts of women older than 32 years old or with overweight/obesity, pregnancy and birth outcomes were also much better in Group 3, albeit without statistical significance.
UNASSIGNED: The addition of both HMG and r-LH to FSH may improve the chance of infertile women with normal ovarian responses to have more success in having live birth babies, specifically in those over 32 years of age or with overweight/obese patients who typically face challenges in conceiving and sustaining a pregnancy.
摘要：
■人类更年期促性腺激素（HMG）/重组黄体生成素（r-LH）与卵泡刺激素（FSH）的添加可以改善卵巢反应不良患者在辅助生殖手术期间的妊娠结局。然而,在这些手术中，它们对卵巢反应正常的患者的影响尚不清楚，这就形成了本研究的目的。
这项回顾性研究纳入了456名接受体外受精或卵胞浆内单精子注射治疗的不育妇女。第1组接受FSH；第2组接受FSH+HMG/r-LH；第3组接受FSH+HMG+r-LH。
■第III组的年龄和体重指数明显更高。II组和III组的子宫内膜厚度更大，提示子宫内膜容受性较好。在第3组中观察到更好的妊娠和分娩结果。在32岁以上或超重/肥胖的女性亚组中，第3组的妊娠和分娩结局也好得多,但无统计学意义.
■在FSH中同时添加HMG和r-LH可能会提高卵巢反应正常的不育妇女在生活产婴儿方面取得更大成功的机会，特别是在32岁以上或超重/肥胖患者中，这些患者通常在怀孕和维持怀孕方面面临挑战。
这项回顾性研究纳入了456名接受体外受精或卵胞浆内单精子注射治疗的不育妇女。第1组接受FSH；第2组接受FSH+HMG/r-LH；第3组接受FSH+HMG+r-LH。
■第III组的年龄和体重指数明显更高。II组和III组的子宫内膜厚度更大，提示子宫内膜容受性较好。在第3组中观察到更好的妊娠和分娩结果。在32岁以上或超重/肥胖的女性亚组中，第3组的妊娠和分娩结局也好得多,但无统计学意义.
■在FSH中同时添加HMG和r-LH可能会提高卵巢反应正常的不育妇女在生活产婴儿方面取得更大成功的机会，特别是在32岁以上或超重/肥胖患者中，这些患者通常在怀孕和维持怀孕方面面临挑战。
